NASDAQ:ERNA Eterna Therapeutics (ERNA) Stock Forecast, Price & News $2.13 +0.04 (+1.91%) (As of 09/27/2023 ET) Add Compare Share Share Today's Range$2.05▼$2.2350-Day Range$2.03▼$2.8952-Week Range$1.90▼$7.15Volume4,167 shsAverage Volume17,733 shsMarket Capitalization$11.52 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileProfileChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media About Eterna Therapeutics (NASDAQ:ERNA) StockEterna Therapeutics Inc. operates as a preclinical-stage, biopharmaceutical company. The company offers Synthetic mRNA, ToRNAdo mRNA Delivery, mRNA Gene Editing, and mRNA Cell Reprogramming. It also develops therapies and medicines using gene-editing proteins and cell therapy technology for the treatment of oncology, blood disorder, and monogenic disease. The company was formerly known as Brooklyn ImmunoTherapeutics, Inc. and changed its name to Eterna Therapeutics Inc. in October 2022. Eterna Therapeutics Inc. is based in Cambridge, Massachusetts.Read More ERNA Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ERNA Stock News HeadlinesSeptember 13, 2023 | uk.finance.yahoo.comStem Cell Therapy Contract Manufacturing market is projected to grow at a CAGR of 12.4% by 2033: VisiongainSeptember 8, 2023 | finance.yahoo.comInsider Stock Buying Reaches US$2.7m On Eterna TherapeuticsSeptember 27, 2023 | Behind the Markets (Ad)66,000% upside on tiny biotech?The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.September 6, 2023 | finance.yahoo.comEterna Therapeutics Teams with Lineage Cell on Transplant TherapiesSeptember 6, 2023 | finance.yahoo.comEterna Therapeutics Announces Initiation of Development Activities for Hypoimmune Pluripotent Cell Line for Neurology Indications Under Partnership With Lineage Cell TherapeuticsSeptember 5, 2023 | finance.yahoo.comEterna Therapeutics Appoints Biopharma Industry Veteran Dorothy Clarke to Board of DirectorsSeptember 5, 2023 | finance.yahoo.comEterna Therapeutics Appoints Dorothy Clarke to Board of DirectorsJuly 18, 2023 | finance.yahoo.comEterna Therapeutics Announces Completion of $8.7 Million of Convertible Debt FinancingSeptember 27, 2023 | Behind the Markets (Ad)66,000% upside on tiny biotech?The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.July 11, 2023 | finance.yahoo.comEterna Therapeutics Appoints Biotech Industry Veterans Brant Binder and Richard Wagner, Ph.D. to Board of DirectorsMay 24, 2023 | finance.yahoo.comEterna Therapeutics Appoints Megan Yung as Chief Strategy Officer, General CounselMay 17, 2023 | finance.yahoo.comEterna Therapeutics and Factor Bioscience Announce New Data on Multi-Cell-Type Therapeutic Approach at American Society of Gene & Cell Therapy (ASGCT) 26th Annual MeetingMay 4, 2023 | finance.yahoo.comEterna Therapeutics to Deliver Eight Presentations at the American Society of Gene & Cell Therapy (ASGCT) 26th Annual MeetingMay 2, 2023 | marketwatch.comEterna Therapeutics Shares Rise 11% After Offer for Exacis Biotherapeutics AssetsMay 2, 2023 | finance.yahoo.comEterna Therapeutics Acquires Allogeneic Immuno-Oncology Platform from Exacis BiotherapeuticsApril 11, 2023 | marketwatch.comEterna Therapeutics Agrees to $10M Stock Purchase with Lincoln Park CapitalApril 11, 2023 | finance.yahoo.comEterna Therapeutics and Lincoln Park Capital Enter into a Common Stock Purchase Agreement for Up To $10 MillionMarch 28, 2023 | finance.yahoo.comJeff Karp, Ph.D., Joins Eterna’s Scientific Advisory BoardMarch 24, 2023 | seekingalpha.comERNA Eterna Therapeutics Inc.March 20, 2023 | finance.yahoo.comEterna Therapeutics Reports Financial Results for Fourth Quarter and Full Year 2022 and Recent Business HighlightsMarch 16, 2023 | finance.yahoo.comInsiders might want to re-evaluate their US$2.7m stock purchase as Eterna Therapeutics Inc. (NASDAQ:ERNA) drops to US$16mFebruary 3, 2023 | finance.yahoo.comTreadwell Therapeutics Announces the Appointment of Roger Sidhu, M.D., as Chief Medical OfficerJanuary 26, 2023 | msn.comEterna Therapeutics chief medical officer to resignJanuary 5, 2023 | marketwatch.comEterna Therapeutics Names Matt Angel as Permanent President, CEO >ERNAJanuary 4, 2023 | msn.comEterna appoints Matt Angel as CEO, PresidentJanuary 4, 2023 | finance.yahoo.comEterna Therapeutics Appoints Matt Angel, Ph.D. as Chief Executive Officer and PresidentDecember 20, 2022 | finance.yahoo.comIn a New Audio Interview, Toni Loudenbeck of Traders News Source Interviews Dr. Matt Angel, CEO Eterna TherapeuticsSee More Headlines Receive ERNA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Eterna Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address ERNA Company Calendar Last Earnings8/11/2023Today9/27/2023Next Earnings (Estimated)11/13/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ERNA CUSIPN/A CIK748592 Webwww.brooklynitx.com Phone(212) 582-1199Fax760-438-3505Employees9Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($5.64) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-24,580,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-270.24% Return on Assets-82.57% Debt Debt-to-Equity RatioN/A Current Ratio0.54 Quick Ratio0.54 Sales & Book Value Annual Sales$5.80 million Price / Sales1.98 Cash FlowN/A Price / Cash FlowN/A Book Value$4.12 per share Price / Book0.51Miscellaneous Outstanding Shares5,410,000Free Float3,493,000Market Cap$11.47 million OptionableNot Optionable Beta4.27 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesDr. Matthew Angel Ph.D. (Age 42)CEO & Pres Comp: $240.8kMs. Sandra M. Gurrola (Age 56)Principal Financial & Accounting Officer and VP of Fin. Ms. Megan YungChief Strategy OfficerKey CompetitorsVYNE TherapeuticsNASDAQ:VYNECingulateNASDAQ:CINGLandos BiopharmaNASDAQ:LABPComera Life SciencesNASDAQ:CMRAAeterna ZentarisNASDAQ:AEZSView All CompetitorsInsiders & InstitutionsSippican Capital AdvisorsBought 8,101 shares on 8/15/2023Ownership: 0.410%Goldman Sachs Group Inc.Bought 11,284 shares on 8/15/2023Ownership: 0.214%BlackRock Inc.Sold 5,591 shares on 8/11/2023Ownership: 0.337%John D HalpernBought 335,920 shares on 12/2/2022Total: $1.10 M ($3.28/share)Nicholas Jason SingerBought 283,286 shares on 12/2/2022Total: $929,178.08 ($3.28/share)View All Insider TransactionsView All Institutional Transactions ERNA Stock - Frequently Asked Questions How have ERNA shares performed in 2023? Eterna Therapeutics' stock was trading at $3.22 at the beginning of the year. Since then, ERNA stock has decreased by 34.2% and is now trading at $2.12. View the best growth stocks for 2023 here. Are investors shorting Eterna Therapeutics? Eterna Therapeutics saw a increase in short interest in September. As of September 15th, there was short interest totaling 130,500 shares, an increase of 21.3% from the August 31st total of 107,600 shares. Based on an average trading volume of 12,800 shares, the days-to-cover ratio is currently 10.2 days. Currently, 4.4% of the company's shares are sold short. View Eterna Therapeutics' Short Interest. When is Eterna Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, November 13th 2023. View our ERNA earnings forecast. How were Eterna Therapeutics' earnings last quarter? Eterna Therapeutics Inc. (NASDAQ:ERNA) announced its earnings results on Friday, August, 11th. The company reported ($0.85) earnings per share for the quarter. What is Eterna Therapeutics' stock symbol? Eterna Therapeutics trades on the NASDAQ under the ticker symbol "ERNA." Who are Eterna Therapeutics' major shareholders? Eterna Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include Sippican Capital Advisors (0.41%), BlackRock Inc. (0.34%) and Goldman Sachs Group Inc. (0.21%). Insiders that own company stock include John D Halpern and Nicholas Jason Singer. View institutional ownership trends. How do I buy shares of Eterna Therapeutics? Shares of ERNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Eterna Therapeutics' stock price today? One share of ERNA stock can currently be purchased for approximately $2.12. How much money does Eterna Therapeutics make? Eterna Therapeutics (NASDAQ:ERNA) has a market capitalization of $11.47 million and generates $5.80 million in revenue each year. The company earns $-24,580,000.00 in net income (profit) each year or ($5.64) on an earnings per share basis. How can I contact Eterna Therapeutics? Eterna Therapeutics' mailing address is 10355 Science Center Drive SUITE 150, San Diego CA, 92121. The official website for the company is www.brooklynitx.com. The company can be reached via phone at (212) 582-1199, via email at investors@brooklynitx.com, or via fax at 760-438-3505. This page (NASDAQ:ERNA) was last updated on 9/27/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eterna Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.